)

ARS Pharmaceuticals (SPRY) investor relations material
ARS Pharmaceuticals Cantor Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Launch progress and market access
Ten months into launch, with initial focus on improving access and converting large payers from prior authorization to open access.
Direct-to-consumer (DTC) campaign began in May/June, with linear TV ads starting in July, expected to drive uptake.
About 10,000 doctors have prescribed the product, with early adopters showing increased prescribing rates over time.
Physician adoption is growing as awareness and patient education increase, especially among early adopters.
Emphasis on making access easier for doctors and educating patients and caregivers.
Marketing strategy and consumer engagement
Jingle-based advertising was chosen over celebrity endorsements for memorability and cost-effectiveness.
The campaign slogan "Hello Nephi, Goodbye Needles" highlights the product's unique, needle-free profile.
Commercials emphasize device size, convenience, and include a free carry case, with plans to include the case in the product box by end of Q1.
Market research shows aided awareness rose from 20% to 49% after the campaign, with positive trends in patient intent to discuss and request prescriptions.
The campaign resonates especially with parents and caregivers, focusing on ease of use and reduced anxiety.
Sales dynamics and prescription trends
Discontinuation of the GoodRx program in July led to a temporary drop in cash pay prescriptions and market share, but improved overall revenue quality.
Cash sales are a small portion of the market and are less profitable; focus is on insured patients and education about the $199 BlinkRx option.
Back-to-school season creates a surge in pediatric renewals, but high doctor workload limits new product discussions during this period.
About 50% of annual prescriptions are for new patients, with higher renewal rates among children.
Average co-pay for the product is $37, lower than generic auto-injectors, with 80% of commercially insured patients paying $25 or less.
Next ARS Pharmaceuticals earnings date

Next ARS Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage